On 17 May 2006 the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Veraflox 15 mg, 60 mg and 120 mg tablets for cats and dogs, and Veraflox 25 mg/ml oral suspension for cats. The applicant requested a re-examination of the opinion. After having considered the grounds for this request, the CVMP re-examined the initial opinion, and confirmed the recommendation of the refusal of the marketing authorisation application on 14 September 2006.
The company who applied for a marketing authorisation is Bayer HealthCare AG.
Questions and answers on the recommendation for refusal of a marketing authorisation application for Veraflox (PDF/35.59 KB)
First published: 24/01/2007
Last updated: 24/01/2007
|International non-proprietary name (INN) or common name||
Bayer HealthCare AG
|Date of opinion||
|Date of refusal of marketing authorisation||